Donmez, AyhanZoghi, MehdiCagirgan, SeckinAcarlar, CeylanTombuloglu, Murat2019-10-272019-10-2720061473-0502https://doi.org/10.1016/j.transci.2005.12.007https://hdl.handle.net/11454/38607Background: Infusion of cryopreserved and non-cryopreserved hematopoietic progenitor cells (HPC) is associated with a broad variety of symptoms. In this study, we have investigated infusion-related toxicity regarding temperature of cryopreserved autologous peripheral blood progenitor cells (PBPCs) transplanted in 31 and allogeneic non-cryopreserved PBPCs in 4 patients receiving high dose chemotherapy and stem cells transplantation for hematological malignancies. Study design and method: A 24 h ECG-Holter recording system was used to obtain cardiac arrhythmias. Two milliliters HPC were collected from entrance site of venous access to evaluate the temperature of infused HPC. Results: We have detected arrhythmias in 17 (48.58%) of our patients before, during and after infusion. Median temperature of the infusat was 21 degrees C (18-28.2). Arrhythmias during infusion were detected in 8 (22.85%) patients. The temperatures of infused HPCs were not statistically different in group with and without arrhythmias as 22 degrees C and 21 degrees C, respectively (P > 0.05). And also, volume, contents [dimethylsulphoxide (DMSO), red blood cells (RBC), platelet (PLT), and total nucleated cell (TNQ)] of product, and rate of infusion speed did not have any effect on arrhythmias. Conclusion: As a result of this study, we have concluded that the temperature of HPC does not cause any systemic hypothermia and does not have any relation to arrhythmias detected during infusion. (c) 2006 Elsevier Ltd. All rights reserved.en10.1016/j.transci.2005.12.007info:eu-repo/semantics/closedAccesstemperatureprogenitor cellsarrhythmiasArticle343245251WOS:00024058010000416931400Q3Q4